CONCLUSIONS
A pivotal role of apoptosis is emerging in the pathogenesis of HIV-induced immunosuppression. This immunosuppression involves an increased susceptibility toward opportunistic infections and malignancies that drive their own pathogenesis, in part, by subverting apoptotic signaling pathways.
With the emerging interest in developing therapeutic agents that directly modify apoptotic responses, both HIV infection and complications of HIV are, therefore, candidates for testing the abilities of such agents to alter disease outcomes.REFERENCES
1. Chen, X.M., Gores, G.J., Paya, C.V., and LaRusso, N.F., Cryptosporidium parvum induces apoptosis in biliary epithelia by a Fas/Fas ligand-dependent mechanism, Am. J. Physiol., 277, G599-G608, 1999.
2. Grassme, H., Kirschnek, S., Riethmueller, J., Riehle, A., von Kurthy, G., Lang, F., Weller, M., and Gulbins, E., CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa, Science, 290, 527-530, 2000.
3. Hauser, A.R. and Engel, J.N., Pseudomonas aeruginosa induces type-III-secretion-mediated apoptosis of macrophages and epithelial cells, Infect. Immun., 67, 5530-5537, 1999.
4. Gao, L.Y. and Abu Kwaik, Y., Activation of caspase 3 during Legionella pneumophila-induced apoptosis, Infect. Immun., 67, 4886-4894, 1999.
5. Gao, L.Y. and Abu Kwaik, Y., Apoptosis in macrophages and alveolar epithelial cells during early stages of infection by Legionella pneumophila and its role in cytopathogenicity, Infect. Immun., 67, 862-870, 1999.
6. Fiorentini, C., Fabbri, A., Falzano, L., Fattorossi, A., Matarrese, P., Rivabene, R., and Donelli, G., Clostridium difficile toxin B induces apoptosis in intestinal cultured cells, Infect. Immun., 66, 2660-2665, 1998.
7. Tsai, PJ., Lin, Y.S., Kuo, C.F., Lei, H.Y., and Wu, J.J., Group A streptococcus induces apoptosis in human epithelial cells, Infect.
Immun., 67, 4334-4339, 1999.8. Kim, J.M., Eckmann, L., Savidge, T.C., Lowe, D.C., Witthoft, T., and Kagnoff, M.F., Apoptosis of human intestinal epithelial cells after bacterial invasion, J. Clin. Invest., 102, 1815-1823, 1998.
9. Kornfeld, H., Mancino, G., and Colizzi, V., The role of macrophage cell death in tuberculosis, Cell Death Differ., 6, 71-78, 1999.
10. Hersh, D., Monack, D.M., Smith, M.R., Ghori, N., Falkow, S., and Zychlinsky, A., The salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1, Proc. Natl. Acad. Sci. U.S.A., 96, 2396-2401, 1999.
11. Alnemri, E.S., Livingston, D.J., Nicholson, D.W., Salvesen, G., Thornberry, N.A., Wong, W.W., and Yuan, J., Human ICE/CED-3 protease nomenclature, Cell, 87, 171, 1996.
12. Chen, Y., Smith, M.R., Thirumalai, K., and Zychlinsky, A., A bacterial invasin induces macrophage apoptosis by binding directly to ICE, EMBO J., 15, 3853-3860, 1996.
13. McSorley, S.J., Xu, D., and Liew, F.Y., Vaccine efficacy of salmonella strains expressing glycoprotein 63 with different promoters, Infect. Immun., 65, 171-178, 1997.
14. Zychlinsky, A., Prevost, M.C., and Sansonetti, PJ., Shigella flexneri induces apoptosis in infected macrophages, Nature, 358, 167-169, 1992.
15. Eriksson, B.K., Andersson, J., Holm, S.E., and Norgren, M., Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome, Clin. Infect. Dis., 27, 1428-1436, 1998.
16. Kuo, C.F., Wu, J.J., Tsai, PJ., Kao, F.J., Lei, H.Y., Lin, M.T., and Lin, Y.S., Streptococcal pyrogenic exotoxin B induces apoptosis and reduces phagocytic activity in U937 cells, Infect. Immun., 67, 126-130, 1999.
17. Kroemer, G. and Reed, J.C., Mitochondrial control of cell death, Nat. Med., 6, 513-519, 2000.
18. Muller, A., Gunther, D., Brinkmann, V., Hurwitz, R., Meyer, T.F., and Rudel, T., Targeting of the pro- apoptotic VDAC-like porin (PorB) of Neisseria gonorrhoeae to mitochondria of infected cells, EMBO J., 19, 5332-5343, 2000.
19. Massari, P., Ho, Y., Wetzler, L.M., Neisseria meningitidis porin PorB interacts with mitochondria and protects cells from apoptosis, Proc. Natl. Acad. Sci. U.S.A., 97, 9070-9075, 2000.
20. Galmiche, A., Rassow, J., Doye, A., Cagnol, S., Chambard, J.C., Contamin, S., de Thillot, V., Just,
I., Ricci, V., Solcia, E., Van Obberghen, E., and Boquet, P., The N-terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release, EMBO J., 19, 6361-6370, 2000.
21. Hu, S., Schwartzman, J.D., and Kasper, L.H., Apoptosis within mouse eye induced by Toxoplasma gondii, Chin. Med. J. (Engl.), 114, 640-644, 2001.
22. Kirby, J.E. and Nekorchuk, D.M., Bartonella-associated endothelial proliferation depends on inhibition of apoptosis, Proc. Natl. Acad. Sci. U.S.A., 99, 4656-4661, 2002.
23. Coorey, S., The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival,
J. Gen. Virol., 85, 1065-1076, 2004.
24. Guasparri, I., Keller, S.A., and Cesarman, E., KSHV vFLIP is essential for the survival of infected lymphoma cells, J. Exp. Med., 199, 993-1003, 2004.
25. Zhu, G., Keithly, J.S., and Philippe, H., What is the phylogenetic position of cryptosporidium? Intl. J. Sys. Evol. Microbiol., 50, 1673-1681, 2000.
26. Tzipori, S. and Griffiths, J.K., Natural history and biology of Cryptosporidium parvum, Adv. Para- sitol., 40, 5-36, 1998.
27. O’Donoghue, PJ., Cryptosporidium and cryptosporidiosis in man and animals, Int. J. Parasitol., 25, 139-195, 1995.
28. Xiao, L., Morgan, U.M., Fayer, R., Thompson, R.C., and Lal, A.A., Cryptosporidium systematics and implications for public health, Parasitol. Today, 16, 287-292, 2000.
29. Hoepelman, I.M., Human cryptosporidiosis, Int. J. STD and AIDS, 7, 28-33, 1996.
30. Blunt, D.S., Khramtsov, N.V., Upton, S.J., and Montelone, B.A., Molecular karyotype analysis of Cryptosporidium parvum: evidence for eight chromosomes and a low-molecular-size molecule.
Clin. Diagn. Lab. Immunol., 4, 11-13, 1997.31. Okhuysen, P.C., Chappell, C.L., Crabb, J.H., Sterling, C.R., and DuPont, H.L., Virulence of three distinct Cryptosporidium parvum isolates for healthy adults, J. Infect. Dis., 180, 1275-1281, 1999.
32. Chen, X.M., Keithly, J.S., Paya, C.V., and LaRusso, N.F., Cryptosporidiosis, N. Engl. J. Med., 346, 1723-1731, 2002.
33. Meinhardt, P.L., Casemore, D.P., and Miller, K.B., Epidemiologic aspects of human cryptosporidiosis and the role of waterborne transmission, Epidemiol. Rev., 18, 118-136, 1996.
34. Guerrant, R.L., Cryptosporidiosis: an emerging, highly infectious threat, Emerg. Infect. Dis., 3, 51-57, 1997.
35. Miller, J.R., Decreasing cryptosporidiosis among HIV-infected persons in New York City, 1995-1997, J. Urban Health, 75, 601-602, 1998.
36. Carr, A., Marriott, D., Field, A., Vasak, E., and Cooper, D.A., Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy, Lancet, 351, 256-261, 1998.
37. Clark, D.P., New insights in human cryptosporidiosis, Clin. Microbiol. Rev., 12, 554-563, 1999.
38. Farthing, M.J., Clinical aspects of human cryptosporidiosis, Contrib. Microbiol., 6, 50-74, 2000.
39. Hunter, P.R. and Nichols, G., Epidemiology and clinical features of crypto sporidium infection in immunocompromised patients, Clin. Microbiol. Rev., 15, 145-154, 2002.
40. Manabe, Y.C., Clark, D.P., Moore, R.D., Lumadue, J.A., Dahlman, H.R., Belitsos, P.C., Chaisson, R.E., and Sears, C.L., Cryptosporidiosis in patients with AIDS: correlates of disease and survival, Clin. Infect. Dis., 27, 536-542, 1998.
41. Argenzio, R.A., Liacos, J.A., Levy, M.L., Meuton, D.J., Lecce, J.G., and Powell, D.W., Villous atrophy, crypt hyperplasia, cellular infiltration, and impaired glucose-Na+ absorption in enteric cryptosporidiosis of pigs, Gastroenterology, 98, 1129-1140, 1990.
42. Lumadue, J.A., Manabe, Y.C., Moore, R.D., Belitsos, P.C., Sears, C.L., and Clark, D.P., A clinico- pathologic analysis of AIDS-related cryptosporidiosis, AIDS, 12, 2459-2566, 1998.
43. Teixidor, H.S., Godwin, T.A., and Ramirez, E.A., Cryptosporidiosis of the biliary tract in AIDS, Radiology, 180, 51-56, 1991.
44. Hasan, F.A., Jeffers, L.J., Dickinson, G., Otrakji, C.L., Greer, PJ., Reddy, K.R., and Schiff, E.R., Hepatobiliary cryptosporidiosis and cytomegalovirus infection mimicking metastatic cancer to the liver, Gastroenterology, 100, 1743-1748, 1991.
45. Chen, X.M., Levine, S.A., Tietz, P., Krueger, E., McNiven, M.A., Jefferson, D.M., Mahle, M., and LaRusso, N.F., Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism, Hepatology, 28, 906-913, 1998.
46. McCole, D.F., Eckmann, L., Laurent, F., and Kagnoff, M.F., Intestinal epithelial cell apoptosis following Cryptosporidium parvum infection, Infect. Immun., 68, 1710-1713, 2000.
47. Ojcius, D.M., Perfettini, J.L., Bonnin, A., and Laurent, F., Caspase-dependent apoptosis during infection with Cryptosporidium parvum, Microbes Infect., 1, 1163-1168, 1999.
48. Widmer, G., Corey, E.A., Stein, B., Griffiths, J.K., and Tzipori, S., Host cell apoptosis impairs Cryptosporidium parvum development in vitro, J. Parasitol., 86, 922-928, 2000.
49. McCole, D.F., Eckmann, L., Laurent, F., and Kagnoff, M.F., Intestinal epithelial cell apoptosis following Cryptosporidium parvum infection, Infect. Immun., 68, 1710-1713, 2000.
50. Motta, I., Gissot, M., Kanellopoulos, J.M., and Ojcius, D.M., Absence of weight loss during cryptosporidium infection in susceptible mice deficient in Fas-mediated apoptosis, Microbes Infect., 4, 821-827, 2002.
51. Deng, M., Rutherford, M.S., and Abrahamsen, M.S., Host intestinal epithelial response to Cryptosporidium parvum, Adv. Drug Deliv. Rev., 56, 869-884, 2004.
52. Thornburn, A., Death receptor-induced cell killing, Cell. Signalling, 16, 139-144, 2004.
53. Beg, A.A. and Baltimore, D., An essential role for NF-B in preventing TNF--induced cell death, Science, 274, 782-784, 1996.
54. Laurent, F., Eckmann, L., Savidge, T.C., Morgan, G., Theodos, C., Naciri, M., and Kagnoff, M.F., Cryptosporidium parvum infection of human intestinal epithelial cells induces the polarized secretion of C-X-C chemokines, Infect.
Immun., 65, 5067-5073, 1997.55. Laurent, F., Kagnoff, M.F., Savidge, T.C., Naciri, M., and Eckmann, L., Human intestinal epithelial cells respond to Cryptosporidium parvum infection with increased prostaglandin H synthase 2 expression and prostaglandin E2 and F2 production, Infect. Immun., 66, 1787-1790, 1998.
56. Seydel, K.B., Zhang, T., Champion, G.A., Fichtenbaum, C., Swanson, P.E., Tzipori, S., Griffiths, J.K., and Stanley, S.L., Jr., Cryptosporidiumparvum infection of human intestinal xenografts in SCID mice induces production of human tumor necrosis factor and interleukin-8, Infect. Immun., 66, 2379-2382,
1998.
57. Vollenweider, J.M., Chen, X.M., Gores, S.J., Paya, C.V., and LaRusso, N.F., HIV-1 Tat protein enhances Cryptosporidium parvum-induced apoptosis in cultured human biliary epithelia, Hepatology, 34i A268, 2001.
58. Chen, X.M. and LaRusso, N.F., Mechanisms of attachment and internalization of Cryptosporidium parvum to biliary and intestinal epithelial cells, Gastroenterology, 118, 368-379, 2000.
59. Verdon, R., Keusch, G.T., Tzipori, S., Grubman, S.A., Jefferson, D.M., and Ward, H.D., An in vitro model of infection of human biliary epithelial cells by Cryptosporidium parvum, J. Infect. Dis., 175, 1268-1272, 1997.
60. Siliciano, R.F., The role of CD4 in HIV envelope-mediated pathogenesis, Curr. Top. Microbiol. Immunol., 205, 159-179, 1996.
61. Townsley-Fuchs, J., Neshat, M.S., Margolin, D.H., Braun, J., and Goodglick, L., HIV-1 gp120: a novel viral B cell superantigen, Int. Rev. Immunol., 14, 325-338, 1997.
62. Jeang, K.T., Xiao, H., and Rich, E.A., Multifaceted activities of the HIV-1 transactivator of transcription, Tat, J. Biol. Chem., 274, 28837-28840, 1999.
63. Schwarze, S.R., Ho, A., Vocero-Akbani, A., and Dowdy, S.F., In vivo protein transduction: delivery of a biologically active protein into the mouse, Science, 285, 1569-1572, 1999.
64. Rappaport, J., Joseph, J., Croul, S., Alexander, G., Del Valle, L., Amini, S., and Khalili, K., Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat, J. Leukocyte Biol., 65, 458-465, 1999.
65. Nath, A., Haughey, N.J., Jones, M., Anderson, C., Bell, J.E., and Geiger, J.D., Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine, Ann. Neurol., 47, 186-194, 2000.
66. Macho, A., Calzado, M.A., Jimenez-Reina, L., Ceballos, E., Leon, J., and Munoz, E., Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis, Oncogene, 18, 7543-7551, 1999.
67. Bartz, S.R. and Emerman, M., Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8, J. Virol., 73, 1956-1963, 1999.
68. Seve, M., Favier, A., Osman, M., Hernandez, D., Vaitaitis, G., Flores, N.C., McCord, J.M., and Flores, S.C., The human immunodeficiency virus-1 Tat protein increases cell proliferation, alters sensitivity to zinc chelator-induced apoptosis, and changes Sp1 DNA binding in HeLa cells, Arch. Biochem. Biophys., 361, 165-172, 1999.
69. Kumar, A., Dhawan, S., Mukhopadhyay, A., and Aggarwal, B.B., Human immunodeficiency virus-1- Tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NF-B, FEBS Lett., 462, 140-144, 1999.
70. Bartz, S.R. and Emerman, M., Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8, J. Virol., 73, 1956-1963,
1999.
71. Re, M.C., Furlini, G., Vignoli, M., Ramazzotti, E., Zauli, G., and La Placa, M., Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients, Clin. Diagn. Lab. Immunol., 3, 230-232, 1996.
72. White, A.C., Jr., Chappell, C.L., Hayat, C.S. et al., Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial, J. Infect. Dis., 170, 419-424, 1994.
73. Rossignol, J.F., Ayoub, A., and Ayers, M.S., Treatment of diarrhea caused by Cryptosporidiumparvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide, J. Infect. Dis., 184, 103-106, 2001.
74. Griffiths, J.K., Treatment for AIDS-associated cryptosporidiosis, J. Infect. Dis., 178, 915-916, 1998.
75. White, A.C., Jr., Cron, S.G., and Chappell, C.L., Paromomycin in cryptosporidiosis, Clin. Infect. Dis., 32, 1516-1517, 2001.
76. Hewitt, R.G., Yiannoutsos, C.T., Higgs, E.S., Carey, J.T., Geisler, PJ., Soave, R., Rosenber, R., Vazquez, G.J., Wheat, L.J., Fass, R.J., Antoninievic, Z., Walawander, A.L., Flanigan, T.P., and Bender, J.F., Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection, Clin. Infect. Dis., 3, 1084-1092, 2000.
77. Woods, K.M. and Upton, S.J., Efficacy of select antivirals against Cryptosporidium parvum in vitro, FEMS Microbiol. Lett., 168, 59-63, 1998.
78. Wilcox, C.M. and Monkemuller, K.E., Hepatobiliary diseases in patients with AIDS: focus on AIDS cholangiopathy and gallbladder disease, Dig. Dis., 16, 205-213, 1998.
79. Kanegane, H., Nomura, K., Miyawaki, T., and Tosato, G., Biological aspects of Epstein-Barr virus (EBV) infected lymphocytes in chronic active EBV infection and associated malignancies, Crit. Rev. Oncol., 44, 239-249, 2002.
80. Knecht, H., Berger, C., Al-Homsi, A.S., McQuain, C., and Brouseet, P., Epstein-Barr virus oncogenesis, Crit. Rev. Oncol./Hemat., 26, 117-135, 1997.
81. Jones, J.F., Shurin, S.J., Abramowsky, C., Tubbs, R.R., Sciotto, C.G., Wahl, R., Sands, J., Gottman, D., Katz, B.Z., and Sklar, J., T-cell lymphomas containing Epstein-Barr virus DNA in patients with chronic Epstein-Barr virus infection, N. Engl. J. Med., 318, 733-741, 1988.
82. Burkitt, D., A sarcoma involving the jaws in African children, Br. J. Surg., 45, 218-223, 1958.
83. Magrath, I.T. and Bhatia, K., Pathogenesis of small noncleaved cell lymphomas (Burkitt's lymphoma), in The Non-Hodgkin’s Lymphomas, 2nd ed., Magrath, I.T., Ed., Arnold, New York, 1997, pp. 385-409.
84. Knowles, D.M., Immunodeficiencies-associated lymphoproliferative disorders, Mod. Pathol., 12, 200-217, 1999.
85. Okano, M., Nakanishi, M., Taguchi, Y., Sakiyama, Y., and Matsumoto, S., Primary immunodeficiency diseases and Epstein-Barr virus-induced lymphoproliferative disorders, Act. Paediatr. Jpn., 34, 385-392, 1992.
86. Hoshino, Y., Kimura, H., Kuzushima, K., Tsurumi, T., Nemoto, K., Kikuta, A., Nishiyama, Y., Kojima, S., Matsuyama, T., and Morishima, T., Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load, Bone Marrow Transplant., 26, 199-201, 2000.
87. Aoki, Y., Joknes, K.D., and Tosato, G., Kaposi's sarcoma—associated herpesvirus-encoded interleukin-6, J. Hematother. Stem Cell Res., 9, 137-145, 2000.
88. Harabuchi, Y., Yamanaka, N., Kataura, A., Imai, S., Kinoshita, T., Mizuno, F., and Osato, T., Epstein- Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma, Lancet, 335, 128-130, 1990.
89. Eliopoulos, A.G. and Young, L.S., LMP1 structure and signal transduction, Sem. in Cancer Biol., 11, 435-444, 2001.
90. Liebowitz, D., Wang, D., and Kieff, E., Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus, J. Virol., 58, 233-237, 1986.
91. Moorthy, R.K. and Thorley-Lawson, D.A., Biochemical, genetic and functional analyses of the phosphorylation sites of the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1, J. Virol., 67, 2637-2645, 1993.
92. Wang, D., Liebowitz, D., and Kieff, E., An ENV membrane protein expressed in immortalized lymphocytes transforms established rodent cells, Cell, 43, 831-840, 1985.
93. Peng, M. and Lundgren, E., Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis, Oncogene, 7, 1775-1782, 1992.
94. Huen, D.S., Henderson, S.A., Croom-Carter, D., and Rowe, M., The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain, Oncogene, 10, 549-560, 1995.
95. Kieff, E., Epstein-Barr virus and its replication, in Fundamental Virology, Fileds, B.N., Knipe, D.M., Howley, P.M., Knipe, D.M., and Howley, P.M., Eds., Lippincott-Raven, Philadelphia, 1996, pp. 1109-1163.
96. Wang, D., Liebowitz, D., Wang, F., Gregory, C., Rickinson, A., Larson, R., Springer, T., and Kieff, E., Epstein-Barr latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity, J. Virol., 62, 4173-4184, 1988.
97. Laherty, C.D., Hu, H.M., Opipari, A.W., Wang, F., and Dixit, V.M., The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activatin nuclear factor B, J. Biol. Chem., 34, 24157-24160, 1992.
98. Hammarskjold, M.L. and Simurada, M.C., Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-B activity, J. Virol., 66, 6496-6501, 1992.
99. Herrero, J.A., Mathew, P., and Paya, C.V., LMP1 activates NF-B by targeting the inhibitory molecule iKBα, J. Virol., 69, 2168-2174, 1995.
100. Li, H.P. and Chang, Y.S., Epstein-Barr virus latent membrane protein 1: structure and function, J. Biomed. Sci., 10, 490-504, 2003.
101. Eliopoulos, A.G., Gallagher, N.J., Blake, S.M., Dawson, C.W., and Young, L.S., Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus encoded latent membrane protein 1 coregulates interleukin 6 and interleukin 8 production, J. Biol. Chem., 274, 16085-16096, 1999.
102. Izumi, K.M., Kaye, K.M., and Kieff, E.D., The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation, Proc. Natl. Acad. Sci. U.S.A., 94, 1447-1452, 1997.
103. Eliopoulos, A.G., Blake, S.M., Floettmann, J.E., Rowe, M., and Young, L.S., Epstein-Barr virus encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2, J. Virol., 73, 1023-1035, 1999.
104. Baker, S.J. and Reddy, E.P., Modulation of life and death by the TNF receptor superfamily, Oncogene, 17, 3261-3270, 1998.
105. Floettmann, J.E., Ward, K., Rickinson, A.B., and Rowe, M., Cytostatic effect of Epstein-Barr virus latent membrane protein analyzed using tetracycline-regulated expression in B cell lines, Virology, 223, 29-40, 1996.
106. Cuomo, L., Ramquist, T., Trivedi, P., Wang, F., Klein, G., and Masucci, M.G., Expression of the Epstein Barr virus (EBV) encoded membrane protein LMP1 impairs the in vitro growth, clonability, and tumorigenicity of an EBV-negative Burkitt lymphoma line, Int. J. Cancer, 51, 949-955, 1992.
107. Rowe, M., Lear, A.L., Croom-Carter, D., Davies, A.H., and Rickinson, A.B., Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes, J. Virol., 66, 122-131, 1992.
108. Yates, J.L., Warren, N., and Sugden, B., Stable replication of plasmids derived from Epstein-Barr virus genome, Nature, 310, 812-815, 1984.
109. Niller, H.H., Salamon, D., Ilg, K., Koroknai, A., Banati, F., Schwarzmann, F., Wolf, H., and Minarovits, J., EBV-associated neoplasms: alternative pathogenetic pathways, Med. Hypoth., 62, 387-391, 2004.
110. Wilson, J.B. and Levine, A.J., The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice, Curr. Top. Microbiol. Immunol., 182, 375-384, 1992.
111. Rooney, C., Howe, J.G., Speck, S.H., and Miller, G., Influences of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing PJ3-HR-1 strain of Epstein-Barr virus, J. Virol., 63, 1531-1539, 1989.
112. Yalamanchili, R., Tong, X., Grossman, S., Johannsen, E., Mosialos, G., and Kieff, E., Genetic and biochemical evidence that EBNA2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV, Virology, 204, 634-641, 1994.
113. Dambaugh, T., Hennessy, K., Chamnankit, L., and Kieff, E., U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen-2, Proc. Natl. Acad. Sci. U.S.A., 81, 7632-7636, 1984.
114. Rickinson, A.B., Young, L.S., and Rowe, M., Influence of the Epstein-Barr virus nuclear antigen EBNA2 on the growth phenotype of virus transformed B cells, J. Virol., 61, 1310-1317, 1987.
115. Farrell, C.J., Lee, J.M., Shin, E.-C., Cebrat, M., Cole, P.A., and Hayward, S.D., Inhibition of Epstein- Barr virus induced growth proliferation by a nuclear antigen EBNA2-TAT peptide, Proc. Nat. Acad. Sci. U.S.A., 101, 4625-4630, 2004.
116. Krauer, K.G., Burgess, A., Buck, M., Flanagan, J., Sculley, T.B., and Gabrielli, B., The EBNA-3 gene family proteins disrupt the G2/M checkpoint, Oncogene, 23, 1342-1353, 2004.
117. Cannell, E.J., Farrell, PJ., and Sinclair, A.J., Epstein-Barr virus disrupts the normal cell pathway to regulate Rb activity during immortalisation of primary B cells, Oncogene, 13, 1413-1421, 1996.
118. Parker, G.A., Touitou, R., and Allday, M.J., Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis, Oncogene, 19, 700-709,
2000.
119. Alfieri, C., Birkenbach, M., and Kieff, E., Early events in Epstein-Barr virus infection of human B lymphocytes, Virology, 181, 595-608, 1991.
120. Matsuda, G., Nakajima, K., Kawaguchi, Y., Yamanashi, Y., and Hiria, K., Epstein-Barr virus (EBV) nuclear antigen leader protein (EBNA-LP) forms complexes with a cellular anti-apoptosis protein Bcl2 or its ENV counterpart BHRF1 through hHS1-associated protein X-1, Microbiol. Immunol., 47, 91-99, 2003.
121. Yin, X.M., Oltvai, A.N., and Korsmeyer, S.J., BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax, Nature, 369, 321-323, 1994.
122. Swaminathan, S., Molecular biology of Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus, Semin. Hematol., 40, 107-114, 2003.
123. Loughrey, M., Trivett, M., Lade, S., Murray, W., Turner, H., and Waring, P., Diagnostic application of Epstein-Barr virus-encoded RNA in situ hybridization, Pathology, 26(4), 301-308, 2004.
124. Ling, P.D., Vilchez, R.A., Keitel, W.A., Poston, D.G., Peng, R.S., White, Z.S., Visnegarwala, F., Lewis, D.E., and Butel, J.S., Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1- infected patients receiving highly active antiretroviral therapy, Clin. Infect. Dis., 37, 1244-1249, 2004.
125. Glaser, S.L., Clarke, C.A., Gulley, M.L., Craig, F.E., DiGiuseppe, J.A., Dorfman, R.F., Mann, R.B., and Ambinder, R.F., Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998, Cancer, 98, 300-309, 2003.